Table III.

Pairwise comparisons of the GM-CSF-stimulated clonogenic assay in the disease groups.

Pair	GM-CSF (20 ng/ml)	GM-CSF (10 ng/ml0	GM-CSF (5 ng/ml)	GM-CSF (1 ng/ml)	GM-CSF (0.1 ng/ml)	Unstimulated
Controls-NS	0.248	1.000	1.000	1.000	1.000	1.000
Controls-NS/MPD	1.000	1.000	1.000	1.000	0.460	0.010
Controls-JMML	0.079	0.038	0.022	0.010	0.007	0.000
NS-JMML	0.001	0.002	0.004	0.004	0.003	0.000
NS-NS/MPD	0.671	0.808	0.903	0.786	0.674	0.016
NS/MPD-JMML	1.000	1.000	1.000	1.000	1.000	1.000

NS, Noonan syndrome patients, (n=24); NS/MPD, Noonan syndrome patients with myeloproliferative evolution, (n=3); JMML, myelomonocytic leukemia patients, (n=5). Bold print indicates statistically significant p-values (p<0.05; Kruskal-Wallis test). CFU-GM from circulating mononuclear cells cultured in the presence of decreasing GM-CSF concentrations or without GM-CSF (unstimulated).